NexgenRx's Q2 2025 revenue at $4.34-million

Executive Summary

• NexgenRx Inc. reported its financial results for the second quarter ended June 30, 2025, highlighting significant revenue growth and positive EBITDA.
• The company achieved quarterly revenue of $4,346,416, representing an 8.73% increase over the prior-year comparable period, driven by organic growth and the expansion of existing client services.
• The company reported a strong cash position of $2,134,132 and secured a new major client in April, reinforcing its sales pipeline and recurring revenue model.

Key Details

• Quarterly Revenue: $4,346,416 (an increase of $349,043 or 8.73% compared to the prior-year comparable period).
• Year-to-Date Revenue: $8,897,146.
• Quarterly EBITDA: $627,631.
• Net Income Increase: Increased by $321,597 compared to the same period in 2024.
• EBITDA Increase: Increased by $251,131 compared to the same period in 2024.
• Cash Position: $2,134,132.
• Operational Update: Secured a new major client in April from the sales pipeline; IT and implementation teams are currently managing the onboarding process.
• Strategic Outlook: Company cites strong recurring revenues, robust sales pipelines, and an exceptional team as drivers for continued free cash flow generation and value building.

Notable Quotes

• "Each success we share is the result of many hands, one mission, and a shared belief that innovation, teamwork and integrity fuel sustainable growth. Because of our strong recurring revenues, robust sales pipelines and exceptional team, we are well positioned to continue building value for our clients, our people and our shareholders." — Ron Loucks, President and Chief Executive Officer